Mural Oncology announces final cash consideration payable on acquisition close

Mural Oncology (MURA) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (XOMA), XRA 5 Corp. and Mural announced on August 20, the Additional Price Per Share has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition will be $2.035 in cash per share. As previously announced on August 20, 2025, XOMA Royalty, Sub and Mural entered into the Transaction Agreement pursuant to which Sub, a wholly-owned subsidiary of XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural pursuant to an Irish High Court sanctioned “scheme of arrangement” under Chapter 1 of Part 9 of the Irish Companies Act of 2014. The Acquisition is expected to close in early December 2025, subject to the satisfaction of the outstanding closing conditions and the sanction of the Scheme by the Irish High Court.